|
Medical Advocates Darunavir(Prezista/TMC-114) |
 Darunavir Main Page |
 Main
New and Noteworthy |
Home
Page |
Documents
identified with this icon are in Portable Document Format (PDF) and require the
- POSTER
ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naïve patients
E Arathoon, E Baraldi, PL Lim, et al
PDF Poster 
- POSTER
ARTEMIS: Week 48 safety and efficacy of darunavir/r by gender, age and race
J Andrade-Villanueva, G Herrera, P Chiliade, et al
PDF Poster - POSTER
Comparable in-vitro susceptibility and virologic outcome to darunavir in patients infected
with subtype B and subtype non-B HIV isolates participating in the ARTEMIS Phase III trial
I Dierynck, S De Meyer, E Lathouwers, et al
PDF Poster - POSTER
Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir
and carbamazepine
VJ Sekar, F Tomaka, L Lavreys, et al
PDF Poster - POSTER
Dose selection and pharmacokinetics-pharmacodynamics of darunavir coadministered with low-dose ritonavir
in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents
V Sekar, T Van de Casteele, B Van Baelen, et al
PDF Poster - POWERPOINT POSTER
Effects of nucleoside analogues versus ritonavir boosted protease inhibitors on lipid levels – analysis of 12 clinical
trials in 4231 antiretroviral naïve patients
A Hill, B Gazzard
Poster -
Prevalence of major protease inhibitors (PIs) mutations for darunavir and
tipranavir resistance in samples of
experienced HIV patients from Buenos Aires
Abstract -
Resistance to LPV, TPV and DRV according to three different algorithms in
samples from highly
antiretroviral-therapy-
experienced-patients in Mexico City
Abstract -
Higher darunavir plasma levels and genotipic inhibitory quotient in patients
with rapid virological response
Abstract -
Pharmacokinetic interaction between darunavir in combination with low-dose
ritonavir (DRV/r) and
carbamazepine (CBZ)
Abstract -
Darunavir resistance related mutations in Mexican patients
Abstract -
The use of darunavir/ritonavir as intensification in low viremic HIV-infected
patients treated with boosted protease
inhibitor containing regimens
Abstract -
Combination antiretroviral treatment (CART) with darunavir/ritonavir (DRV/r) and
raltegravir (RAL) in patients with
multidrug resistant (MDR) HIV-1 infection in a community-based setting through an expanded access protocol
(EAP)
Abstract -
Combined darunavir (DRV) and etravirine (TMC125; ETR) resistance analysis of the
pooled DUET trials:
when can we spare the other new classes?
Abstract -
Comparable virologic response and in vitro susceptibility to darunavir in
patients infected with subtype B
and non-subtype B HIV isolates participating in the ARTEMIS Phase III Trial
